Moderna Recognizes the Success of Operation Warp Speed and Affirms Its Ongoing Commitment to Transparency

Cambridge, MA – September 3, 2025 — Moderna is committed to transparency and welcomes the opportunity to highlight the extensive research regarding our COVID-19 vaccine, which has been published in hundreds of peer-reviewed publications and shared with regulators. 

Moderna is a research-driven, American company and we are immensely proud of the role we played in the historic achievements of Operation Warp Speed. As President Trump said at the time, “we are the most exceptional nation in the history of the world… American companies were the first to produce a verifiably safe and effective vaccine.” These vaccines helped end the COVID-19 pandemic, re-open economies and save millions of lives. 

Since 2021, the real-world effectiveness and safety of the vaccines have been confirmed by governments and health systems around the world. Moderna itself has conducted vaccine effectiveness studies every year, in more than 5 million people to-date. These studies consistently show that the Moderna COVID-19 vaccine confers a high degree of protection against hospitalizations among the most vulnerable. We have also actively monitored the safety of the more than one billion doses administered to-date, and have always transparently shared those results with regulators and with the public, including through peer-reviewed publications and presentations. We will continue to do so as part of our commitment to transparency. 

The promise of mRNA is immense. The same technology that helped turn the tide of a global pandemic is now paving the way for breakthroughs in cancer, autoimmune and rare diseases. To help ensure Americans have clear and accessible information, Moderna will be compiling previously disclosed information on our website at the link here.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of Moderna's COVID vaccines; the potential for Moderna’s platform to address rare diseases and cancer; and Moderna’s publication of vaccine data. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.